Navigation Links
Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
Date:2/1/2008

WALTHAM, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will release financial results for the fourth quarter and fiscal year ended December 31, 2007 on Wednesday, February 6, 2008 prior to the opening of the U.S. financial markets. A conference call will be held at 8:30 a.m. Eastern Time with Steven Rauscher, President and CEO, and other members of Oscient's management team. The Company announced preliminary revenue results of approximately $80 million for fiscal year 2007 on January 14, 2008.

What: Fourth Quarter and Fiscal Year 2007 Financial Results

When: February 6, 2008 at 8:30 am Eastern Time

How: Domestic participants can access the call by dialing

1-888-634-4009.

International participants are asked to dial 1-706-634-5451. The call

will also be webcast through the Company's website at

http://www.oscient.com.

Contact: Christopher Taylor, 781-398-2466 or Sarah Emond, 781-398-2544

A replay will be available two hours after the conclusion of the call until February 13, 2008. Domestic participants can access the replay by dialing 1-800-642-1687, while international participants are asked to dial 1-706-645-9291. The conference ID number for the replay is 33514080. A replay will also be available through http://www.oscient.com.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States; ANTARA(R) (fenofibrate) capsules, a cardiovascular product and FACTIVE(R) (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient promotes ANTARA and FACTIVE through a nationwide sales force calling on primary care physicians, cardiologists, endocrinologists and pulmonologists. The Company also has a novel, late-stage antibiotic candidate, Ramoplanin, for the treatment of Clostridium difficile-associated disease (CDAD).

For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at http://www.antararx.com and http://www.factive.com. For a complete description of the risks associated with our business please refer to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2007 and in other filings that we may make with the Securities and Exchange Commission from time to time.


'/>"/>
SOURCE Oscient Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
2. Webcast Alert: HCA Announces 4Q-Year End 07 Earnings Report
3. Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast
4. CBIZ Webcasts Fourth-Quarter and Year-End 2007 Conference Call
5. RESMED to Webcast Second Quarter 2008 Earnings Conference Call
6. Coherent, Inc. to Webcast First Fiscal Quarter 2008 Results
7. Moog Inc. Announces First Quarter 2008 Earnings Webcast on January 25, 2008
8. BD Announces Webcast of Annual Meeting of Shareholders
9. PPD Announces Fourth Quarter and Year-End 2007 Earnings Release, Webcast and Conference Call
10. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
11. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... CO (PRWEB) , ... June 20, 2017 , ... ... a report contending that the introduction of school choice can promote economic development ... a charter school that has, according to the report, contributed to the economic ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider ... the clinical trials market. Similar to its approach in demonstrating positive outcomes in the ... marketplace by proving the value of eVisits to support virtual studies. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... Leading dental clinicians, Drs. Ashlyn ... with the VATECH PaX-i and Anatomage systems. With advanced digital images and modeling capabilities, ... place dental implants precisely and restore oral health for those who are missing ...
(Date:6/20/2017)... , ... June 20, 2017 , ... As a leading ... the link between stroke and gum disease. Those with bleeding gums in Vancouver, BC, ... untreated, this condition can lead to heart disease, stroke and diabetes. Drs. Parviz Roshan, ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with advanced capabilities ... scanner provides higher-resolution images than traditional MRIs, enabling doctors to get a more ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/12/2017)... Inc., a biotechnology company focused on the development of novel ... and Head of Virology Kristin Bedard has been invited to ... Beyond meeting sponsored by Life Science Washington.  This Symposium ... PDT at the Agora Conference Center in Seattle, ... joined by other leaders in infectious disease research and the ...
Breaking Medicine Technology: